

2018 Pancreatitis Drug Development- Pipeline Analysis Report

https://marketpublishers.com/r/215D581BFD6EN.html

Date: May 2018

Pages: 0

Price: US\$ 999.00 (Single User License)

ID: 215D581BFD6EN

Abstracts

With an estimated prevalence of around 20 million pancreatitis cases worldwide, it is one of the most devastative gastrointestinal diseases. On the basis of duration of the disease existence, it is typically classified as acute pancreatitis and chronic pancreatitis. Of this, acute pancreatitis lasts from few days to months and can occur suddenly. On the other hand, the chronic pancreatitis develops over years and can last for few years.

Around 25 companies and universities are focusing on developing treatment options for Pancreatitis.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Pancreatitis pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Pancreatitis pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Pancreatitis pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.



Contents

1 TABLE OF CONTENTS

- 1.1 List of Figures
- 1.2 List of Tables

2 PANCREATITIS PIPELINE ANALYSIS

- 2.1 Disease and Pipeline Overview
- 2.2 Pancreatitis Pipeline Snapshot
- 2.3 Pancreatitis Pipeline by Phase
- 2.4 Pancreatitis Pipeline by Company
- 2.5 Pancreatitis Pipeline by Mechanism of Action

3 PANCREATITIS- COMPANY WISE PIPELINE ANALYSIS

AzurRx BioPharma

Bessor Pharma LLC

Bharat Serums And Vaccines Ltd

CalciMedica

Centeer BioTherapeutics

Centeer BioTherapeutics

Cypralis

DiaMedica Therapeutics

Generon (Shanghai) Corp

GlaxoSmithKline

GNT Pharma

Immungenetics

LipimetiX Development

MallInckrodt

Pharming Group

Stason Pharmaceuticals

Sun BioPharma

Takeda Pharmaceutical

4 PANCREATITIS R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details



Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN PANCREATITIS PIPELINE

6 APPENDIX

- 6.1 About VPA Research
- 6.2 Sources and Research Methodology



List Of Figures

LIST OF FIGURES

- Figure 2: Pancreatitis Pipeline by Companies, H1- 2018
- Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
- Figure 4: Pancreatitis Pipeline by Mechanism of Action, H1- 2018
- Figure 5: Mechanism Wise Pipeline Drug Phases, H1-2018



List Of Tables

LIST OF TABLES

- Table 1: Pancreatitis Pipeline by Phase, H1- 2018
- Table 2: Pancreatitis Pipeline by Companies, H1- 2018
- Table 3: Pancreatitis Pipeline by Mechanism of Action, H1-2018
- Table 4: AzurRx BioPharma Pancreatitis Pipeline, May 2018
- Table 5: Bessor Pharma LLC Pancreatitis Pipeline, May 2018
- Table 6: Bharat Serums And Vaccines Ltd Pancreatitis Pipeline, May 2018
- Table 7: CalciMedica Pancreatitis Pipeline, May 2018
- Table 8: Centeer BioTherapeutics Pancreatitis Pipeline, May 2018
- Table 9: Centeer BioTherapeutics Pancreatitis Pipeline, May 2018
- Table 10: Cypralis Pancreatitis Pipeline, May 2018
- Table 11: Cypralis Pancreatitis Pipeline, May 2018
- Table 12: DiaMedica Therapeutics Pancreatitis Pipeline, May 2018
- Table 13: Generon (Shanghai) Corp Pancreatitis Pipeline, May 2018
- Table 14: GlaxoSmithKline Pancreatitis Pipeline, May 2018
- Table 15: GNT Pharma Pancreatitis Pipeline, May 2018
- Table 16: Immungenetics Pancreatitis Pipeline, May 2018
- Table 17: LipimetiX Development Pancreatitis Pipeline, May 2018
- Table 18: MallInckrodt Pancreatitis Pipeline, May 2018
- Table 19: Pharming Group Pancreatitis Pipeline, May 2018
- Table 20: Stason Pharmaceuticals Pancreatitis Pipeline, May 2018
- Table 21: Sun BioPharma Pancreatitis Pipeline, May 2018



I would like to order

Product name: 2018 Pancreatitis Drug Development- Pipeline Analysis Report

Product link: https://marketpublishers.com/r/215D581BFD6EN.html

Price: US\$ 999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/215D581BFD6EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:		
Last name:		
Email:		
Company:		
Address:		
City:		
Zip code:		
Country:		
Tel:		
Fax:		
Your message:		
	**All fields are required	
	Custumer signature	

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970